| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5375 | 2021 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ... The Lancet 396 (10249), 467-478, 2020 | 2790 | 2020 |
| Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ... The Lancet 396 (10267), 1979-1993, 2020 | 1686 | 2020 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1353 | 2021 |
| Evidence of escape of SARS-CoV-2 variant B. 1.351 from natural and vaccine-induced sera D Zhou, W Dejnirattisai, P Supasa, C Liu, AJ Mentzer, HM Ginn, Y Zhao, ... Cell 184 (9), 2348-2361. e6, 2021 | 1144 | 2021 |
| Reduced neutralization of SARS-CoV-2 B. 1.1. 7 variant by convalescent and vaccine sera P Supasa, D Zhou, W Dejnirattisai, C Liu, AJ Mentzer, HM Ginn, Y Zhao, ... Cell 184 (8), 2201-2211. e7, 2021 | 491 | 2021 |
| Neutralization of SARS-CoV-2 by destruction of the prefusion spike J Huo, Y Zhao, J Ren, D Zhou, HME Duyvesteyn, HM Ginn, L Carrique, ... Cell host & microbe 28 (3), 445-454. e6, 2020 | 372 | 2020 |
| Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays. Nature Protocols, 1-33, 2021 | 242* | 2021 |
| Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity KA Ryan, KR Bewley, SA Fotheringham, GS Slack, P Brown, Y Hall, ... Nature communications 12 (1), 81, 2021 | 164 | 2021 |
| Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig model SD Dowall, A Bosworth, R Watson, K Bewley, I Taylor, E Rayner, L Hunter, ... Journal of general virology 96 (12), 3484-3492, 2015 | 142 | 2015 |
| Dengue virus serotype 3, Karachi, Pakistan B Jamil, R Hasan, A Zafar, K Bewley, J Chamberlain, V Mioulet, ... Emerging infectious diseases 13 (1), 182, 2007 | 135 | 2007 |
| Assessment of the protective effect of Imvamune and Acam2000 vaccines against aerosolized monkeypox virus in cynomolgus macaques GJ Hatch, VA Graham, KR Bewley, JA Tree, M Dennis, I Taylor, ... Journal of virology 87 (14), 7805-7815, 2013 | 134 | 2013 |
| Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19 FJ Salguero, AD White, GS Slack, SA Fotheringham, KR Bewley, ... Nature Communications 12 (1), 1260, 2021 | 127 | 2021 |
| Real-time PCR system targeting a chromosomal marker specific for Bacillus anthracis MH Antwerpen, P Zimmermann, K Bewley, D Frangoulidis, H Meyer Molecular and cellular probes 22 (5-6), 313-315, 2008 | 91 | 2008 |
| Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model PC Proud, D Tsitoura, RJ Watson, BY Chua, MJ Aram, KR Bewley, ... EBioMedicine 63, 2021 | 87 | 2021 |
| Amplicon based MinION sequencing of SARS-CoV-2 and metagenomic characterisation of nasopharyngeal swabs from patients with COVID-19 SC Moore, R Penrice-Randal, M Alruwaili, X Dong, ST Pullan, DP Carter, ... MedRxiv, 2020.03. 05.20032011, 2020 | 77 | 2020 |
| Nosocomial buffalopoxvirus infection, Karachi, Pakistan A Zafar, R Swanepoel, R Hewson, M Nizam, A Ahmed, A Husain, ... Emerging Infectious Diseases 13 (6), 902, 2007 | 61 | 2007 |
| Intranasal infection of ferrets with SARS-CoV-2 as a model for asymptomatic human infection HE Everett, FZX Lean, AMP Byrne, PM van Diemen, S Rhodes, J James, ... Viruses 13 (1), 113, 2021 | 58 | 2021 |
| Animal models of Q fever (Coxiella burnetii) KR Bewley Comparative medicine 63 (6), 469-476, 2013 | 56 | 2013 |
| Amplicon-based detection and sequencing of SARS-CoV-2 in nasopharyngeal swabs from patients with COVID-19 and identification of deletions in the viral genome that encode … SC Moore, R Penrice-Randal, M Alruwaili, N Randle, S Armstrong, ... Viruses 12 (10), 1164, 2020 | 52 | 2020 |
Simon G P FunnellHealth Protection Agency在 ukhsa.gov.uk 的电子邮件经过验证
